A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC


Study Number
826120
Phase
II
Age Group
Adult
Purpose

This will be an open-label, phase 2 study in which subjects will receive ISA101b and cemiplimab.

Full Title

A Phase II Study of cemiplimab, an anti-PD-1 monoclonal antibody, and ISA101b vaccine in patients with recurrent/metastatic HPV16 positive Oropharyngeal Cancer who have experienced disease progression with prior anti-PD-1 therapy

ClinicalTrials.Gov ID
NCT04398524

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.